Items Tagged ‘temozolomide’

June 7th, 2016

Temodar® After Radiation Improves Survival in Anaplastic Gliomas

By

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Anaplastic gliomas are a type of brain […]

View full entry

Tags: 2016, Anaplastic gliomas, asco, Brain Cancer, CATNON trial, General Brain Cancer, News, radiation therapy, Temodar, temozolomide


May 12th, 2016

Avastin®/Camptosar® Improves Outcomes Compared with Temodar® in Glioblastoma

By

The treatment combination consisting of Avastin (bevacizumab) plus Camptosar (irinotecan) improves time to cancer progression compared to treatment with Temodar (temozolomide) in patients with newly diagnosed glioblastoma. These results were recently published in the Journal of Clinical Oncology. Glioblastoma is an extremely aggressive form of brain cancer. Standard therapy includes surgery to remove as much […]

View full entry

Tags: avastin, bevacizumab, Brain Cancer, Campostar, glioblastoma, irinotecan, News, nonmethylated O6-methylguanine–DNA methyltransferase promotor, Temodar, temozolomide


February 17th, 2016

Immune Therapy for Brain Tumors: A New Promising Avenue

By

  Glioblastoma is a particularly aggressive type of brain cancer. Only about one fifth of adults diagnosed with it survive two years or more after their diagnosis. A new two-drug combination, currently in early clinical trials, might help people diagnosed with glioblastoma to fight the disease. In a presentation of early clinical trial data to […]

View full entry

Tags: Brain Cancer, clinical trial, glioblastoma, immune inhibitor, indoximod, News, temozolomide, UNM CCC


October 22nd, 2015

Optune Approved for Newly Diagnosed Glioblastoma Multiforme

By

The United States Food and Drug Administration has expanded the approval of the Optune device for the treatment of patients with newly diagnosed glioblastoma multiforme. Glioblastoma multiforme (GBM) is an extremely aggressive form of brain cancer. Average survival of patients with GBM is less than 15 months because the cancer tends to be resistant to […]

View full entry

Tags: Brain Cancer, gbm, General Brain Cancer, glioblastoma multiforme, News, Optune device, temozolomide, TTFields